Latest Production Development News

Bio-Gene Technology Limited is progressing its development of two novel insecticidal compounds, Qcide and Flavocide, targeting major global markets with strong commercial validation and significant US Department of Defense funding.

Bio-Gene Technology Limited has raised $2.1 million through a placement and launched a Share Purchase Plan to fund critical safety studies for its flagship insecticide Flavocide®, alongside development of Qcide and strategic initiatives.

Enlitic, Inc. has launched a two-tranche institutional placement to raise A$10 million, underpinning its strategic collaboration with GE HealthCare and fueling expansion in AI-enabled medical imaging data migration.

Enlitic has formalised a binding MOU with GE HealthCare to deliver multi-million-dollar migration services, contingent on raising A$10 million through a new capital placement. This partnership and funding round mark a pivotal step in Enlitic’s growth strategy within AI-driven medical imaging.

Codeifai Limited has raised $250,000 through unsecured convertible loans, positioning the company to accelerate platform development and marketing ahead of its upcoming AGM.

WiseTech Global has confirmed its participation in the strategic review process initiated by US-based e2open, amid media speculation of a potential acquisition. While discussions remain preliminary with no certainty of a deal, the move aligns with WiseTech’s ongoing acquisition-driven growth strategy.

BluGlass Limited has launched a $6 million Share Purchase Plan (SPP) offering new shares with attaching options to eligible shareholders, aiming to fund the scale-up of its visible laser production and support ongoing product development.

HITIQ Ltd has successfully completed a $680,000 placement and launched a $2.92 million rights issue, positioning the company to fund its strategic shift towards the consumer market and expand its footprint in the US.

Anagenics Limited reported a cash outflow of $424K for Q3 2025 but maintains robust liquidity with $1.48 million in available funding, supported by a mix of secured and unsecured loans.

BlinkLab Limited has raised A$7.66 million through a well-supported placement to accelerate FDA regulatory trials for its autism and ADHD diagnostic platforms, leveraging its innovative smartphone-based technology.

Anatara Lifesciences has obtained a $400,000 loan advance from a major shareholder group against its estimated R&D tax refund for the first half of FY2025, providing crucial funding to support ongoing clinical trials and product development without immediate capital raising.

8common Limited reported a record Q3 FY25 SaaS and transaction revenue of $1.1 million, alongside a 33% reduction in operational costs, supported by technology upgrades and a $1.5 million financing facility.